The head of Novo Nordisk’s controlling shareholder is looking to invest a share of the firm’s Wegovy obesity drug windfall in Britain, saying that it remains a “very appealing” investment destination.
Kasim Kutay, the chief executive of Novo Holdings, which manages $150 billion of assets, said the “UK will see strong inflows” from the investment company in the biotechnology and life sciences sectors.
The comments from Kutay, 58, a British citizen and Labour Party donor, will be seen as a boost to attempts to attract overseas investment and to turn the country into a life sciences “superpower”.
Novo Holdings, which manages the assets of the Novo Nordisk Foundation philanthropic organisation, owns about 28 per cent of the shares in Novo Nordisk and 77 per cent
